Overview

• Medical technology firm's Q1 revenue rose 1.6%, beating analyst expectations

• Adjusted EPS for Q1 beat analyst estimates

• Company to complete combination of Biosciences and Diagnostic Solutions with Waters Corp

Outlook

• BD affirms FY26 revenue growth guidance for New BD as low single-digit plus

• New BD FY26 adjusted diluted EPS expected between $12.35 and $12.65

Result Drivers

• CONNECTED CARE GROWTH - Revenue in the Connected Care segment grew 5.5%, driven by advancements in medication management and patient monitoring systems

• INTERVENTIONAL SEGMENT - The Interventional segment saw a 5.8% revenue increase, supported by new product clearances and portfolio expansions

• BIOPHARMA INVESTMENT - $110 mln investment in U.S. pharmaceutical supply chain to expand syringe production and support biologic drug delivery

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 10 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for Becton Dickinson and Co is $210.00, about 0% above its February 6 closing price of $210.02

• The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 12 three months ago

Press Release: ID:nPn7hmDZMa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)